Pulmonary arterial hypertension (PAH) is a multifaceted and lethal disorder characterized by elevated pulmonary pressures and right ventricular failure, ultimately leading to premature death. With an extensive understanding of the pathophysiological mechanisms underlying PAH, pharmacological treatment has largely progressed to targeted agents. Nonetheless, PAH persists as a progressive condition with unsatisfactory survival rates, and current treatments are inadequate in halting disease advancement.
